Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (June 2019)
53 slides from Ac Immune Sa's shareholder meeting presentation, Jun 28, 2019
Slide 1: Roadmap to successful therapies for neurodegenerative diseases
www.acimmune.com © 2019 AC Immune. Not to be used or reproduced without permission. Roadmap to successful therapies for neurodegenerative diseases NASDAQ: ACIU | Annual General Meeting | June 2019 Version June 28
Slide 2: Agenda
© 2019 AC Immune. Not to be used or reproduced without permission. 2 NASDAQ: ACIU | Annual General Meeting | June 2019 ▪ AC Immune’s roadmap to successful therapies for neurodegenerative disease ▪ AC Immune’s revised business strategy ▪ Focus on more homogeneous Alzheimer’s disease populations ▪ Ach
Slide 3: Disclaimer
© 2019 AC Immune. Not to be used or reproduced without permission. 3 NASDAQ: ACIU | Annual General Meeting | June 2019 Disclaimer This presentation may contain statements that constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
Slide 4: AC Immune's roadmap to successful therapies for neurodegenerative diseases
AC Immune’s roadmap to successful therapies for neurodegenerative diseases Andrea Pfeifer, CEO
Slide 5: Precision medicine is a key driver for effective treatments
© 2019 AC Immune. Not to be used or reproduced without permission. 5 NASDAQ: ACIU | Annual General Meeting | June 2019 (1) Reardon S, Nature 2018 ; (2) Pontecorvo MJ, et al ., Brain 2019 ; (3) Gordon BA, et al., Brain 2019 ; (4) Strydom A, et al ., Alzheimers Dement (N Y) 2018 ; (5) Lott IT and Head
Slide 6: AC Immune's revised business strategy
AC Immune’s revised business s trategy
Slide 7: Vision and dual proprietary technology platforms
© 2019 AC Immune. Not to be used or reproduced without permission. 7 NASDAQ: ACIU | Annual General Meeting | June 2019 Vision SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Morphomer TM Conformation - sensitive small molecules To become a global leader in precision
Slide 8: Precision medicine enables combination therapies
© 2019 AC Immune. Not to be used or reproduced without permission. 8 NASDAQ: ACIU | Annual General Meeting | June 2019 Precision medicine enables combination therapies AC Immune is focused on detecting and treating AD 1 earlier (1) Alzheimer’s disease; (2) Mild cognitive impairment ▪ Future treatmen
Slide 9: Company strengths: broad pipeline and solid financial position
© 2019 AC Immune. Not to be used or reproduced without permission. 9 NASDAQ: ACIU | Annual General Meeting | June 2019 ▪ Addressing largest market opportunity in healthcare ▪ Pioneering precision medicine in neurodegenerative diseases ▪ CHF 302 million in cash, supports operations through Q3 2023 1
Slide 10: Highly committed institutional investors and corporate funding to date
© 2019 AC Immune. Not to be used or reproduced without permission. 10 NASDAQ: ACIU | Annual General Meeting | June 2019 Investors and funds from partnerships Highly committed institutional investors 1 Five private financing rounds IPO NASDAQ September 2016 Share capital offering of 10 million common
Slide 11: Precision medicine ultimately creates differentiation
© 2019 AC Immune. Not to be used or reproduced without permission. 11 NASDAQ: ACIU | Annual General Meeting | June 2019 Precision medicine ultimately creates differentiation AC Immune’s strategy for successful AD treatment Vision Alzheimer’s disease (AD) Non - AD NeuroOrphans Diagnostics Technology
Slide 12: ACIU's development in rare diseases
© 2019 AC Immune. Not to be used or reproduced without permission. 12 NASDAQ: ACIU | Annual General Meeting | June 2019 ACIU’s development in rare diseases US data Disease/Condition Incidence (per 100,000) Patient p opulation ('000) 2 AD Alzheimer's disease PD Parkinson's disease FTD Frontotemporal
Slide 13: Pipeline and catalysts 2019/20
Pipeline and catalysts 2019/ 20
Slide 14: Driven by proprietary technology platforms for sustained growth
© 2019 AC Immune. Not to be used or reproduced without permission. 14 NASDAQ: ACIU | Annual General Meeting | June 2019 Driven by proprietary technology platforms for sustained growth TARGETS PRODUCT CANDIDATE INDICATION DISCOVERY PRECLIN PHASE 1 PHASE 2 PHASE 3 PARTNERS Tau Anti - Tau antibody AD 1
Slide 15: Key milestones for 2019/20
© 2019 AC Immune. Not to be used or reproduced without permission. 15 NASDAQ: ACIU | General Assembly | June 2019 Key milestones for 2019/ 20 Successful delivery of strategy with multiple near - term catalysts ACI - 24 ACI - 35 a - synuclein TDP - 43 a - synuclein PET tracer Morphomer Tau Phase 1b i
Slide 16: Focus on more homogeneous Alzheimer's disease populations
Focus on more homogeneous Alzheimer's disease populations
Slide 17: Tau and beta-amyloid are major hallmarks of neurodegeneration
© 2019 AC Immune. Not to be used or reproduced without permission. 17 NASDAQ: ACIU | Annual General Meeting | June 2019 Tau and beta - amyloid are major hallmarks of neurodegeneration AD d evelops because of a complex series of events in the brain over a long period of time Genetics, lifestyle and e
Slide 18: Two categories of genes influence whether a person develops AD
© 2019 AC Immune. Not to be used or reproduced without permission. 18 NASDAQ: ACIU | Annual General Meeting | June 2019 Two categories of genes influence whether a person develops AD Genetic populations APOE - e4 PSEN1 E280A mutation Down syndrome APOE - e4 gene Risk genes increase the likelihood of
Slide 19: Why study genetic populations
© 2019 AC Immune. Not to be used or reproduced without permission. 19 NASDAQ: ACIU | Annual General Meeting | June 2019 Why study genetic populations Credit: Greg Kendall - Ball/Nature “ It has haunted me all of my life but I want to be prepared if possible Elenith is enrolled in a study of people w
Slide 20: Crenezumab prevention study in Colombian population
© 2019 AC Immune. Not to be used or reproduced without permission. 20 NASDAQ: ACIU | Annual General Meeting | June 2019 Target Misfolded Abeta Licensee Key results ▪ Humanized IgG4 antibody 2,3 ▪ Designed to neutralize Abeta oligomers by 3 : ▪ Blocking the interaction of oligomers with neurons ▪ Pro
Slide 21: ACI-24 Phase 1b in Down syndrome
© 2019 AC Immune. Not to be used or reproduced without permission. 21 NASDAQ: ACIU | Annual General Meeting | June 2019 Target Misfolded Abeta Study rationale ▪ Down syndrome population is at high risk of developing AD ▪ 75 – 100% of people with Down syndrome have AD by age 60 ▪ Unique possibility t
Slide 22: Achievements 2018/19
Achievements 2018/19
Slide 23: Highlights and achievements 2018/19: Business operations
© 2019 AC Immune. Not to be used or reproduced without permission. 23 NASDAQ: ACIU | Annual General Meeting | June 2019 Business Operations ▪ License agreement signed with Eli Lilly in December 2018 to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzh
Slide 24: Highlights and achievements 2018/2019: Finance
© 2019 AC Immune. Not to be used or reproduced without permission. 24 NASDAQ: ACIU | Annual General Meeting | June 2019 Highlights and achievements 2018/2019 Finance ▪ Enhanced cash position CHF 302 million as of Q1 2019 ▪ R eceipt of CHF 80 million upfront payment and USD 50 million convertible not
Slide 25: Clinical stage programs highlights and achievements
© 2019 AC Immune. Not to be used or reproduced without permission. 25 NASDAQ: ACIU | Annual General Meeting | June 2019 Clinical stage programs Highlights and achievements 2018/19 Anti - Tau antibody 1 ▪ Commenced recruitment for a second Phase 2 trial of RG6100 (MTAAU9937A, RO7105705) in moderate A
Slide 26: Clinical stage and Phase 1 ready programs
© 2019 AC Immune. Not to be used or reproduced without permission. 26 NASDAQ: ACIU | Annual General Meeting | June 2019 Clinical stage and Phase 1 ready programs Highlights and achievements 2018/19 Morphomer - a - synuclein - PET tracer ▪ The first - in - human trial for the potentially first select
Slide 27: Pre-clinical stage programs
© 2019 AC Immune. Not to be used or reproduced without permission. 27 NASDAQ: ACIU | Annual General Meeting | June 2019 Pre - clinical stage programs Highlights and achievements 2018/19 Morphomer neuroinflammation ▪ First NLRP3 small molecule inhibitors identified and further testing of analogues on
Slide 28: AC Immune: Finance
AC Immune: Finance Joerg Hornstein, CFO
Slide 29: Key financial data
© 2019 AC Immune. Not to be used or reproduced without permission. 29 NASDAQ: ACIU | General Assembly | June 2019 Key financial data 1 For the year ended December 31, 2018 2017 Change (in CHF million except per share data) Revenues 7.2 20.3 (13.1) R&D expenses (44.3) (32.7) (11.6) G&A expenses (12.5
Slide 30: Strategic outlook
Strategic outlook
Slide 31: Strategy for value creation
© 2019 AC Immune. Not to be used or reproduced without permission. 31 NASDAQ: ACIU | Annual General Meeting | June 2019 Strategy for value creation 3. INVEST to further build leadership in neurodegenerative diseases ▪ Execute in line with our “Roadmap” ▪ Focus on Tau and new targets in neuroinflamma
Slide 32: Shaping the future of neurodegeneration
© 2019 AC Immune. Not to be used or reproduced without permission. 32 NASDAQ: ACIU | Annual General Meeting | June 2019 We continue to shape the future of neurodegeneration by discovering and developing breakthrough therapies through pioneering science and precision medicine AC Immune
Slide 33: AGM Agenda Items and Proposals of the Board of Directors
AGM Agenda Items and Proposals of the Board of Directors
Slide 34: Agenda
© 2019 AC Immune. Not to be used or reproduced without permission. 34 NASDAQ: ACIU | Annual General Meeting | June 2019 Agenda 1. Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2018 2. Appropriation of Loss 3. Dis
Slide 35: Approval of the Annual Report and Financial Statements
© 2019 AC Immune. Not to be used or reproduced without permission. 35 NASDAQ: ACIU | Annual General Meeting | June 2019 Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2018 ▪ The Board proposes to approve the Annua
Slide 36: Appropriation of Loss
© 2019 AC Immune. Not to be used or reproduced without permission. 36 NASDAQ: ACIU | Annual General Meeting | June 2019 Appropriation of Loss ▪ The Board of Directors proposes that the net loss of the year 2018 in the amount of KCHF 48'894 is added to the loss brought forward of KCHF 58'426 resultin
Slide 37: Discharge of the Board of Directors and the Executive Committee
© 2019 AC Immune. Not to be used or reproduced without permission. 37 NASDAQ: ACIU | Annual General Meeting | June 2019 Discharge of the Members of the Board of Directors and the Executive Committee ▪ The Board proposes that the members of the Board and the Executive Committee are discharged from th
Slide 38: Compensation: Board non-performance-related compensation
© 2019 AC Immune. Not to be used or reproduced without permission. 38 NASDAQ: ACIU | Annual General Meeting | June 2019 Compensation for the Members of the Board of Directors and the Executive Committee ▪ The Board of Directors proposes to hold the following separate votes on the non - performance -
Slide 39: Compensation: Equity for Board members
© 2019 AC Immune. Not to be used or reproduced without permission. 39 NASDAQ: ACIU | Annual General Meeting | June 2019 Compensation for the Members of the Board of Directors and the Executive Committee ▪ The Board of Directors proposes to hold the following separate votes on the non - performance -
Slide 40: Compensation: Executive Committee non-performance-related
© 2019 AC Immune. Not to be used or reproduced without permission. 40 NASDAQ: ACIU | Annual General Meeting | June 2019 Compensation for the Members of the Board of Directors and the Executive Committee ▪ The Board of Directors proposes to hold the following separate votes on the non - performance -
Slide 41: Compensation: Executive Committee variable compensation
© 2019 AC Immune. Not to be used or reproduced without permission. 41 NASDAQ: ACIU | Annual General Meeting | June 2019 Compensation for the Members of the Board of Directors and the Executive Committee ▪ The Board of Directors proposes to hold the following separate votes on the non - performance -
Slide 42: Compensation: Equity for Executive Committee
© 2019 AC Immune. Not to be used or reproduced without permission. 42 NASDAQ: ACIU | Annual General Meeting | June 2019 Compensation for the Members of the Board of Directors and the Executive Committee ▪ The Board of Directors proposes to hold the following separate votes on the non - performance -
Slide 43: Election of the Members of the Board
© 2019 AC Immune. Not to be used or reproduced without permission. 43 NASDAQ: ACIU | Annual General Meeting | June 2019 Election of the Members of the Board ▪ The Board of Directors proposes for a term until the end of the next ordinary General Meeting ▪ the re - election of Douglas Williams as memb
Slide 44: Election of the Members of the Board (individual votes)
© 2019 AC Immune. Not to be used or reproduced without permission. 44 NASDAQ: ACIU | Annual General Meeting | June 2019 Election of the Members of the Board ▪ The Board of Directors proposes for a term until the end of the next ordinary General Meeting 5a. Re - election of Douglas Williams as member
Slide 45: Dr. Roy E. Twyman
Dr. Roy E. Twyman
Slide 46: Dr. Roy E. Twyman biography
© 2019 AC Immune. Not to be used or reproduced without permission. 46 NASDAQ: ACIU | Annual General Meeting | June 2019 ▪ CEO and founder, Amron Neuroscience, LLC ▪ Spent almost 20 years at Janssen Research & Development , LLC (a Johnson & Johnson company): ▪ M ember of the Neuroscience Therapeutic
Slide 47: Election to the Compensation, Nomination & Corporate Governance Committee
© 2019 AC Immune. Not to be used or reproduced without permission. 47 NASDAQ: ACIU | Annual General Meeting | June 2019 Election to the Compensation, Nomination & Corporate Governance Committee ▪ The Board of Directors proposes the re - election of Martin Velasco, Tom Graney and Douglas Williams as
Slide 48: Election of the Independent Proxy
© 2019 AC Immune. Not to be used or reproduced without permission. 48 NASDAQ: ACIU | Annual General Meeting | June 2019 Election of the Independent P roxy ▪ The Board of Directors proposes to elect Reymond & Associés , represented by Denis Cherpillod , avocat , Avenue de la Gare 1, case postale 7255
Slide 49: Re-election of the Auditors
© 2019 AC Immune. Not to be used or reproduced without permission. 49 NASDAQ: ACIU | Annual General Meeting | June 2019 Re - election of the Auditors ▪ The Board of Directors proposes to re - elect PricewaterhouseCoopers SA, in Pully , for a term of office of one year Agenda item 8
Slide 50: Authorized Share Capital
© 2019 AC Immune. Not to be used or reproduced without permission. 50 NASDAQ: ACIU | Annual General Meeting | June 2019 Authorized Share Capital ▪ Withdrawn by the Board of Directors Agenda item 9
Slide 51: Conditional Capital Increase for Bonds and Similar Debt Instruments
© 2019 AC Immune. Not to be used or reproduced without permission. 51 NASDAQ: ACIU | Annual General Meeting | June 2019 Conditional Capital Increase for Bonds and Similar Debt Instruments ▪ Withdrawn by the Board of Directors Agenda item 10
Slide 52: Conditional Capital Increase for Employee Benefit Plans
© 2019 AC Immune. Not to be used or reproduced without permission. 52 NASDAQ: ACIU | Annual General Meeting | June 2019 Conditional Capital Increase for Employee Benefit Plans ▪ T he Board of Directors proposes to replace the existing first paragraph of article 3c (Conditional Capital Increase for E
Slide 53: We thank you for coming and your continued support
© 2019 AC Immune. Not to be used or reproduced without permission. 53 NASDAQ: ACIU | Annual General Meeting | June 2019 We thank you for coming and your continued support AC Immune